Oncology (all articles)
Single-arm Study | Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation.
11 Jul, 2022 | 11:56h | UTCExtended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (free registration required)
Commentary on Twitter
This single-arm objective performance criteria trial indicated excellent efficacy and safety profile of the second-generation high-frequency irreversible electroporation as primary treatment for localized prostate cancer. https://t.co/FheqcxJeA5
— JAMA Surgery (@JAMASurgery) July 7, 2022
Cohort Study | Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.
11 Jul, 2022 | 11:53h | UTCAuthor Interview: High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade – JAMA
Commentaries:
Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC – medwire News
Commentary on Twitter
Very high levels of tumor mutational burden (TMB) are associated with benefit from #immunotherapy in NSCLC across PD-L1 expression levels and increased CD8+ T cells infiltration. https://t.co/qbq00ZzjFO #LCSM
— JAMA Oncology (@JAMAOnc) June 22, 2022
Long-term analysis of a Phase 2 RCT | Fulvestrant plus capivasertib vs. placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive, HER2-negative breast cancer.
11 Jul, 2022 | 11:48h | UTCNews Release: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University
M-A | Associations of thiazide use with skin cancers.
8 Jul, 2022 | 11:55h | UTCAssociations of thiazide use with skin cancers: a systematic review and meta-analysis – BMC Medicine
Related:
Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma – JAMA Internal Medicine
RCT | Cabozantinib plus atezolizumab vs. sorafenib for advanced hepatocellular carcinoma.
8 Jul, 2022 | 11:41h | UTCInvited Commentary: Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy – The Lancet Oncology (free registration required)
Commentary on Twitter
In the phase III COSMIC-312 trial in 837 pts with advanced-stage HCC, mPFS was 6.8 vs 4.2 months (HR 0.63; P=.0012) & mOS was 15.4 vs 15.5 months (HR 0.90; P=.44) with cabozantinib+atezolizumab vs sorafenib; mPFS with cabozantinib alone was 5.8 months: https://t.co/eiZEqSxLAr
— NatureRevClinOncol (@NatRevClinOncol) July 6, 2022
RCT | Efficacy and safety of a Pegasparaginase-based chemotherapy regimen vs. an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal Natural Killer/T-Cell Lymphoma.
8 Jul, 2022 | 11:21h | UTCEfficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Step Toward Improved Treatment of a Rare Virus-Associated Cancer – JAMA Oncology (free for a limited period)
See also: Visual Abstract
Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children.
8 Jul, 2022 | 11:20h | UTC
Commentaries on Twitter
A multigene classifier reveals that malignant pediatric thyroid nodules have a unique molecular landscape vs those in adults. The classifier had a sensitivity of 96% & specificity of 78% for cancer detection & might reduce the need for diagnostic surgery: https://t.co/hdsPjGe9IR
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Pediatric thyroid cancer is on the rise. Its genomic landscape is unique; but, this retrospective case series shows that it may still be amenable to molecular classification—potentially decreasing diagnostic surgery & opening avenues for targeted therapy. https://t.co/KiYMsB1qGM
— JAMA Oncology (@JAMAOnc) June 10, 2022
RCT | Orteronel for metastatic hormone-sensitive prostate cancer.
8 Jul, 2022 | 11:18h | UTCCommentary: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay
Commentary on Twitter
⛔ SWOG-1216: Orteronel did not improve overall survival for metastatic hormone sensitive #ProstateCancer ➡️ https://t.co/aejFNEb7bM #JCO #PCSM @theNCI @SWOG @neerajaiims @shilpaonc pic.twitter.com/LP5oHQqSIg
— Journal of Clinical Oncology (@JCO_ASCO) May 6, 2022
M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.
7 Jul, 2022 | 12:17h | UTC
M-A | Adjuvant treatments of adult melanoma.
7 Jul, 2022 | 12:12h | UTC
Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.
6 Jul, 2022 | 11:39h | UTCPodcast | Overview of checkpoint inhibitors for general practitioners.
6 Jul, 2022 | 11:29h | UTC#342 Checkpoint Inhibitors – The Curbsiders
Network M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
The multicenter cancer of pancreas screening study: impact on stage and survival.
5 Jul, 2022 | 11:46h | UTC
Commentary on Twitter
? The Cancer of Pancreas Screening (CAPS) program achieves early #PancreaticCancer detection and long-term survival with surveillance ➡️ https://t.co/flqUtSvkcg #JCO #pancSM @mggoggins pic.twitter.com/wj6DMXclVC
— Journal of Clinical Oncology (@JCO_ASCO) June 30, 2022
M-A | Risk factors of clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy.
5 Jul, 2022 | 11:32h | UTCGuideline | Malignancy risk stratification for solitary pulmonary nodule.
4 Jul, 2022 | 12:33h | UTCRCT | Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer.
4 Jul, 2022 | 12:19h | UTCRCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.
4 Jul, 2022 | 12:21h | UTC[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck
— The Lancet Haematology (@TheLancetHaem) June 29, 2022
Phase 1 single-arm study | Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma.
4 Jul, 2022 | 12:08h | UTCOncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Oncolytic Virus Infusion Promising as Brain-Stem Glioma Treatment — Phase I trial shows encouraging OS in children with diffuse intrinsic pontine glioma – MedPage Today (free registration required)
2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
UEG and EAES rapid guideline on transanal total mesorectal excision for rectal cancer.
1 Jul, 2022 | 11:33h | UTC
RCT: Oxaliplatin (3 months vs. 6 months) with 6 months of Fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer.
1 Jul, 2022 | 10:59h | UTC
RCT: Effect of a community health worker intervention on acute care use, advance care planning, and patient-reported outcomes among adults with advanced stages of cancer.
1 Jul, 2022 | 10:58h | UTCEffect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
See also: Visual Abstract
RCT: The effect of enhanced recovery after minimally invasive esophagectomy.
1 Jul, 2022 | 10:56h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Visual abstract: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy
Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease
RCT: Effect of Apatinib plus Pegylated Liposomal Doxorubicin vs. Pegylated Liposomal Doxorubicin alone on platinum-resistant recurrent ovarian cancer.
1 Jul, 2022 | 10:37h | UTCSee also: Visual Abstract